Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.

MLA

Tobe, Sheldon W., et al. “Cardiovascular and Renal Outcomes with Telmisartan, Ramipril, or Both in People at High Renal Risk: Results from the ONTARGET and TRANSCEND Studies.” Circulation, vol. 123, no. 10, Mar. 2011, pp. 1098–107. EBSCOhost, https://doi.org/10.1161/CIRCULATIONAHA.110.964171.

APA

Tobe, S. W., Clase, C. M., Gao, P., McQueen, M., Grosshennig, A., Wang, X., Teo, K. K., Yusuf, S., & Mann, J. F. E. (2011). Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies. Circulation, 123(10), 1098–1107. https://doi.org/10.1161/CIRCULATIONAHA.110.964171

Chicago

Tobe, Sheldon W, Catherine M Clase, Peggy Gao, Matthew McQueen, Anja Grosshennig, Xingyu Wang, Koon K Teo, Salim Yusuf, and Johannes F E Mann. 2011. “Cardiovascular and Renal Outcomes with Telmisartan, Ramipril, or Both in People at High Renal Risk: Results from the ONTARGET and TRANSCEND Studies.” Circulation 123 (10): 1098–1107. doi:10.1161/CIRCULATIONAHA.110.964171.